Development of an anti‐SARS‐CoV‐2 monoclonal antibody panel and its applicability as a reagent in high‐throughput fluorescence reduction neutralization and immunohistochemistry assays
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2023 |
| Outros Autores: | , , , , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | por |
| Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
| Texto Completo: | https://www.arca.fiocruz.br/handle/icict/61285 https://doi.org/10.1002/jmv.29111 |
Resumo: | Fundação Oswaldo Cruz. Instituto Carlos Chagas. Laboratório de Virologia Molecular. Curitiba, PR, Brasil. |
| id |
CRUZ_7eeeac3da199b1e38f5f6e7056c18b18 |
|---|---|
| oai_identifier_str |
oai:www.arca.fiocruz.br:icict/61285 |
| network_acronym_str |
CRUZ |
| network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| repository_id_str |
2135 |
| spelling |
Coelho, Gabriela M.Cataneo, Allan Henrique DepieriRaboni, Sonia M.Nogueira, Meri B.Paula, Caroline B. Vaz deAlmeida, Ana C. S. F.Rogerio, Vanessa Z.Zanchin, Nilson Ivo ToninNoronha, Lucia deZanluca, CamilaSantos, Claudia Nunes Duarte dos2023-11-13T13:01:08Z2023-11-13T13:01:08Z2023COELHO, Gabriela M. et al. Development of an anti‐SARS‐CoV‐2 monoclonal antibody panel and its applicability as a reagent in high‐throughput fluorescence reduction neutralization and immunohistochemistry assays. J Med Virol. V.95, n. 29111, p. 1-11, 2023.1096-9071https://www.arca.fiocruz.br/handle/icict/61285https://doi.org/10.1002/jmv.29111porWileyCOVID-19SARS-CoV-2FluorescenceImmunohistochemistryAntibodies, MonoclonalAntibodies, NeutralizingFluorescenciaARNInmunohistoquímicaAnticuerpos MonoclonalesAnticuerpos NeutralizantesFluorescenceARNImmunohistochimieAnticorps monoclonauxAnticorps neutralisantsFluorescênciaRNAImuno-HistoquímicaAnticorpos MonoclonaisAnticorpos NeutralizantesDevelopment of an anti‐SARS‐CoV‐2 monoclonal antibody panel and its applicability as a reagent in high‐throughput fluorescence reduction neutralization and immunohistochemistry assaysinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleFundação Oswaldo Cruz. Instituto Carlos Chagas. Laboratório de Virologia Molecular. Curitiba, PR, Brasil.Fundação Oswaldo Cruz. Instituto Carlos Chagas. Laboratório de Virologia Molecular. Curitiba, PR, Brasil.Universidade Federal do Paraná. Complexo Hospital de Clínicas. Curitiba, PR, Brasil.Universidade Federal do Paraná. Complexo Hospital de Clínicas. Curitiba, PR, Brasil.Pontifícia Universidade Católica do Paraná. Laboratório de Patologia Experimental. Curitiba, PR, Brasil.Pontifícia Universidade Católica do Paraná. Laboratório de Patologia Experimental. Curitiba, PR, Brasil.Fundação Oswaldo Cruz. Instituto Carlos Chagas. Laboratório de Biologia Estrutural e Engenharia de Proteínas. Curitiba, PR, Brasil.Fundação Oswaldo Cruz. Instituto Carlos Chagas. Laboratório de Biologia Estrutural e Engenharia de Proteínas. Curitiba, PR, Brasil.Pontifícia Universidade Católica do Paraná. Laboratório de Patologia Experimental. Curitiba, PR, Brasil.Fundação Oswaldo Cruz. Instituto Carlos Chagas. Laboratório de Virologia Molecular. Curitiba, PR, Brasil.Fundação Oswaldo Cruz. Instituto Carlos Chagas. Laboratório de Virologia Molecular. Curitiba, PR, Brasil.Since its emergence in late 2019, coronavirus disease 2019 (COVID‐19) has caused millions of deaths and socioeconomic losses. Although vaccination significantly reduced disease mortality, it has been shown that protection wanes over time, and that severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) variants of concern (VOCs) may escape vaccine‐derived immunity. Therefore, serological studies are necessary to assess protection in the population and guide vaccine regimens. A common measure of protective immunity is the presence of neutralizing antibodies (nAbs). However, the gold standard for measuring nAbs (plaque reduction neutralization test, or PRNT) is laborious and time‐consuming, limiting its large‐scale applicability. We developed a high‐ throughput fluorescence reduction neutralization assay (FRNA) to detect SARS‐CoV‐2 nAbs. Because the assay relies on immunostaining, we developed and characterized monoclonal antibodies (mAbs) to lower costs and reduce the assay's vulnerability to reagent shortages. Using samples of individuals vaccinated with COVID‐19 and unvaccinated/pre‐pandemic samples, we showed that FRNA results using commercial and in‐house mAbs strongly correlated with those of the PRNT method while providing results in 70% less time. In addition to providing a fast, reliable, and high‐throughput alternative for measuring nAbs, the FRNA can be easily customized to assess SARS‐ CoV‐2 VOCs. Additionally, the mAb we produced was able to detect SARS‐CoV‐2 in pulmonary tissues by immunohistochemistry assays.info:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/61285/1/license.txt5a560609d32a3863062d77ff32785d58MD51ORIGINALJournal_Medical_Virology_2023.pdfJournal_Medical_Virology_2023.pdfapplication/pdf3810665https://www.arca.fiocruz.br/bitstream/icict/61285/2/Journal_Medical_Virology_2023.pdfe0342f57f1a6d5169984058703e04e06MD52icict/612852023-11-13 10:01:09.102oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-11-13T13:01:09Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
| dc.title.en_US.fl_str_mv |
Development of an anti‐SARS‐CoV‐2 monoclonal antibody panel and its applicability as a reagent in high‐throughput fluorescence reduction neutralization and immunohistochemistry assays |
| title |
Development of an anti‐SARS‐CoV‐2 monoclonal antibody panel and its applicability as a reagent in high‐throughput fluorescence reduction neutralization and immunohistochemistry assays |
| spellingShingle |
Development of an anti‐SARS‐CoV‐2 monoclonal antibody panel and its applicability as a reagent in high‐throughput fluorescence reduction neutralization and immunohistochemistry assays Coelho, Gabriela M. COVID-19 SARS-CoV-2 Fluorescence Immunohistochemistry Antibodies, Monoclonal Antibodies, Neutralizing Fluorescencia ARN Inmunohistoquímica Anticuerpos Monoclonales Anticuerpos Neutralizantes Fluorescence ARN Immunohistochimie Anticorps monoclonaux Anticorps neutralisants Fluorescência RNA Imuno-Histoquímica Anticorpos Monoclonais Anticorpos Neutralizantes |
| title_short |
Development of an anti‐SARS‐CoV‐2 monoclonal antibody panel and its applicability as a reagent in high‐throughput fluorescence reduction neutralization and immunohistochemistry assays |
| title_full |
Development of an anti‐SARS‐CoV‐2 monoclonal antibody panel and its applicability as a reagent in high‐throughput fluorescence reduction neutralization and immunohistochemistry assays |
| title_fullStr |
Development of an anti‐SARS‐CoV‐2 monoclonal antibody panel and its applicability as a reagent in high‐throughput fluorescence reduction neutralization and immunohistochemistry assays |
| title_full_unstemmed |
Development of an anti‐SARS‐CoV‐2 monoclonal antibody panel and its applicability as a reagent in high‐throughput fluorescence reduction neutralization and immunohistochemistry assays |
| title_sort |
Development of an anti‐SARS‐CoV‐2 monoclonal antibody panel and its applicability as a reagent in high‐throughput fluorescence reduction neutralization and immunohistochemistry assays |
| author |
Coelho, Gabriela M. |
| author_facet |
Coelho, Gabriela M. Cataneo, Allan Henrique Depieri Raboni, Sonia M. Nogueira, Meri B. Paula, Caroline B. Vaz de Almeida, Ana C. S. F. Rogerio, Vanessa Z. Zanchin, Nilson Ivo Tonin Noronha, Lucia de Zanluca, Camila Santos, Claudia Nunes Duarte dos |
| author_role |
author |
| author2 |
Cataneo, Allan Henrique Depieri Raboni, Sonia M. Nogueira, Meri B. Paula, Caroline B. Vaz de Almeida, Ana C. S. F. Rogerio, Vanessa Z. Zanchin, Nilson Ivo Tonin Noronha, Lucia de Zanluca, Camila Santos, Claudia Nunes Duarte dos |
| author2_role |
author author author author author author author author author author |
| dc.contributor.author.fl_str_mv |
Coelho, Gabriela M. Cataneo, Allan Henrique Depieri Raboni, Sonia M. Nogueira, Meri B. Paula, Caroline B. Vaz de Almeida, Ana C. S. F. Rogerio, Vanessa Z. Zanchin, Nilson Ivo Tonin Noronha, Lucia de Zanluca, Camila Santos, Claudia Nunes Duarte dos |
| dc.subject.other.en_US.fl_str_mv |
COVID-19 SARS-CoV-2 |
| topic |
COVID-19 SARS-CoV-2 Fluorescence Immunohistochemistry Antibodies, Monoclonal Antibodies, Neutralizing Fluorescencia ARN Inmunohistoquímica Anticuerpos Monoclonales Anticuerpos Neutralizantes Fluorescence ARN Immunohistochimie Anticorps monoclonaux Anticorps neutralisants Fluorescência RNA Imuno-Histoquímica Anticorpos Monoclonais Anticorpos Neutralizantes |
| dc.subject.en.en_US.fl_str_mv |
Fluorescence Immunohistochemistry Antibodies, Monoclonal Antibodies, Neutralizing |
| dc.subject.es.en_US.fl_str_mv |
Fluorescencia ARN Inmunohistoquímica Anticuerpos Monoclonales Anticuerpos Neutralizantes |
| dc.subject.fr.en_US.fl_str_mv |
Fluorescence ARN Immunohistochimie Anticorps monoclonaux Anticorps neutralisants |
| dc.subject.decs.en_US.fl_str_mv |
Fluorescência RNA Imuno-Histoquímica Anticorpos Monoclonais Anticorpos Neutralizantes |
| description |
Fundação Oswaldo Cruz. Instituto Carlos Chagas. Laboratório de Virologia Molecular. Curitiba, PR, Brasil. |
| publishDate |
2023 |
| dc.date.accessioned.fl_str_mv |
2023-11-13T13:01:08Z |
| dc.date.available.fl_str_mv |
2023-11-13T13:01:08Z |
| dc.date.issued.fl_str_mv |
2023 |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.citation.fl_str_mv |
COELHO, Gabriela M. et al. Development of an anti‐SARS‐CoV‐2 monoclonal antibody panel and its applicability as a reagent in high‐throughput fluorescence reduction neutralization and immunohistochemistry assays. J Med Virol. V.95, n. 29111, p. 1-11, 2023. |
| dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/61285 |
| dc.identifier.issn.en_US.fl_str_mv |
1096-9071 |
| dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.1002/jmv.29111 |
| identifier_str_mv |
COELHO, Gabriela M. et al. Development of an anti‐SARS‐CoV‐2 monoclonal antibody panel and its applicability as a reagent in high‐throughput fluorescence reduction neutralization and immunohistochemistry assays. J Med Virol. V.95, n. 29111, p. 1-11, 2023. 1096-9071 |
| url |
https://www.arca.fiocruz.br/handle/icict/61285 https://doi.org/10.1002/jmv.29111 |
| dc.language.iso.fl_str_mv |
por |
| language |
por |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
Wiley |
| publisher.none.fl_str_mv |
Wiley |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
| instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
| instacron_str |
FIOCRUZ |
| institution |
FIOCRUZ |
| reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| collection |
Repositório Institucional da FIOCRUZ (ARCA) |
| bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/61285/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/61285/2/Journal_Medical_Virology_2023.pdf |
| bitstream.checksum.fl_str_mv |
5a560609d32a3863062d77ff32785d58 e0342f57f1a6d5169984058703e04e06 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
| repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
| repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
| _version_ |
1813008912365912064 |